AGENUS INC Unrealized Gain (Loss) on Investments
AGENUS INC (AGEN) reported Unrealized Gain (Loss) on Investments of $1.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-08-07
- AGENUS INC unrealized gain (loss) on investments for the quarter ending 2026-06-30 was $3.39M, a 7104.26% increase year-over-year.
- AGENUS INC unrealized gain (loss) on investments for the quarter ending 2026-03-31 was -$1.56M.
- AGENUS INC unrealized gain (loss) on investments for the quarter ending 2025-12-31 was -$6.02M.
- AGENUS INC unrealized gain (loss) on investments for the quarter ending 2025-09-30 was -$20.05M.
- AGENUS INC unrealized gain (loss) on investments for fiscal 2025 was -$26.12M.
- AGENUS INC unrealized gain (loss) on investments for fiscal 2024 was -$1.54M.
- AGENUS INC unrealized gain (loss) on investments for fiscal 2023 was -$2.13M.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.83M 10-Q · filed 2026-08-07 | -$4.20M derived: sum of 3 quarters · filed 2026-08-07 | -$24.25M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$1.56M 10-Q · filed 2026-05-11 | -$7.58M derived: sum of 2 quarters · filed 2026-05-11 | -$27.63M derived: sum of 3 quarters · filed 2026-05-11 | -$27.59M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$6.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$26.07M derived: sum of 2 quarters · filed 2026-03-16 | -$26.03M derived: sum of 3 quarters · filed 2026-08-07 | -$26.12M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$20.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$20.00M derived: sum of 2 quarters · filed 2026-08-07 | -$20.10M 10-Q · filed 2025-11-10 | -$20.54M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$46.00K 10-Q · filed 2026-08-07 | -$485.00K derived: sum of 3 quarters · filed 2026-08-07 | |
| 2025-03-31 | -$93.00K 10-Q · filed 2026-05-11 | -$532.00K derived: sum of 2 quarters · filed 2026-05-11 | ||
| 2024-12-31 | -$439.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$1.54M 10-K · filed 2026-03-16 | ||
| 2024-09-30 | -$1.10M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | -$2.13M 10-K · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |